Product Description: AF-353 (Ro-4) is a potent, selective and orally bioavailable P2X3/P2X2/3 receptor antagonist, with a pIC50 of 8.0 for both human and rat P2X3, and with a pIC50 of 7.3 for human P2X2/3[1][2].
Applications: Cancer-programmed cell death
Formula: C14H17IN4O2
References: [1]Gever JR, et al. AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol. 2010 Jul;160(6):1387-1398./[2]Munoz A, et al. Modulation of bladder afferent signals in normal and spinal cord-injured rats by purinergic P2X3 and P2X2/3receptors. BJU Int. 2012 Oct;110(8 Pt B):E409-414.
CAS Number: 865305-30-2
Molecular Weight: 400.21
Compound Purity: 99.53
Research Area: Cancer
Solubility: DMSO : 83.33 mg/mL (ultrasonic;warming;heat to 60°C)
Target: P2X Receptor